The FDA has expanded the interchangeable designation for Yuflyma (adalimumab-aaty), a biosimilar to Humira, to include all presentations.

The new offering, designed specifically for prefilled syringes used in various applications, complements its 1 mL ImProject ...

“Myoxinol fits into a wider trend of using neuropeptides in skincare, which aim to modulate nerve signalling or muscle ...

Though they are both multiple myeloma drugs with the same mechanism of action, Sanofi’s Sarclisa has had difficulty competing ...

The installation of the new vial, syringe, and cartridge line is expected to take place throughout the coming year.